Cyclin-dependent kinase inhibitors: a survey of the recent patent literature

Bibliography

• SHERR CJ: Cancer cell cycles. Science (1996) 274:1672–1677.
   PubMed Web of Science ®Google Scholar
• ZHAI S, SENDEROWICZ AM, SAUSVILLE EA, FIGG WD: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Phormacother. (2002) 36:905–911.
   PubMed Web of Science ®Google Scholar
• SENDEROWICZ AM: Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol. Ther. (2003) 2(4, Supp1.1):S84–S95.
   Google Scholar
• TETSU 0, MCCORMICK F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 3:233–245.
   PubMed Web of Science ®Google Scholar
• MALUMBRES M, SOTILLO R, SANTAMARIA D et al.: Mammalian cells cycle without the D-type cyclin-dependent kinases CDK4 and CDK6. Cell (2004) 118(4):493–504.
   PubMed Web of Science ®Google Scholar
• FISCHER PM, ENDICOTT J, MEIJER L: Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res. (2003) 5:235–248.
   PubMedGoogle Scholar
• REN S, ROLLINS BJ: Cyclin C/CDK3 promotes Rb-dependent GO exit. Cell (2004) 117:239–251.
   PubMed Web of Science ®Google Scholar
• DYNLACHT B: Regulation of transcription during the cell cycle. Transcript. Fact. (2001) : 85–112.
   Google Scholar
• DE FALCO G, GIORDANO k CDK9: from basal transcription to cancer and AIDS. Cancer Biol. Thera)). (2002) 1(4):342–347.
   PubMed Web of Science ®Google Scholar
• CRUZ JC, TSAI LH: CDK5 deregulation in the pathogenesis of Alzheimer's disease. Curr. Opin. Neurobiol. (2004) 14(3):390–394.
   PubMedGoogle Scholar
• BYTH KF, CULSHAW JD, GREEN S, OAKES SE, THOMAS AP: Imidazo11,2-al pyridines. Part 2: SAP. and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2245–2248.
   Google Scholar
• MISRA RN, MAO HY, KIM KS et al.: (Cycloalkylamino)acy1-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N- [5- [[ [5- (1, 1-dimethylethyl)-2-oxazolyl] methyl] thiol -2-thiazoly11-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. (2004) 47(7): 1719–1728.
   Google Scholar
• MISRA RN, XIAO H, RAWLINS DB et al.:1H-Pyrazolo [3,4-b[pyridine inhibitors of cyclin-dependent kinases. Bioorg. Med. Chem. Lett. (2003) 13(0:1133–1136.
   PubMedGoogle Scholar
• YUE EW, HIGLEY CA, DIMEO SV et al: Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3. J. Med. Chem. (2002) 45(24):5233–5248.
   Google Scholar
• HELAL CJ, SANNER MA, COOPER CB et al.: Discovery and SAP. of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimer's disease. Bioorg. Med. Chem. Lett. (2004) 14:5521–5525.
   Google Scholar
• PEVARELLO P, BRASCA MG, AMICI R et al.: 3-Aminopyrazole inhibitors of CDK2/Cyclin A as antitumor agents. 1. Lead finding. J. Med. Chem. (2004) 47:3367–3380.
   Google Scholar
• D'ALESSIO R, BARGIOTTI A, METZ Set al.: Benzodipyrazoles: a new class of potent CDK2 inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(5):1315–1319.
   Google Scholar
• MOSHINSKY DJ, BELLAMACINA CR, BOISVERT DC et al:SU 9516: Biochemical analysis of C,dk inhibition and crystal structure in complex with CDK2. Biochem. Biophys. Res. Comm. (2003) 310(3):1026–1031.
   PubMedGoogle Scholar
• TANG J, SHEWCHUCK LM, SATO H, HASEGAWA M, WASHIO Y, NISHIGAKI N: Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis. Bioorg. Med. Chem. Lett. (2003) 13:2985–2988.
   PubMed Web of Science ®Google Scholar
• ENGLER TA, FURNESS K, MALHOTRA S et al.: Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo16,7-alpyrrolo13,4-dcarbazoles. Bioorg. Med. Chem. Lett. (2003) 13(14):2261–2267.
   PubMedGoogle Scholar
• NAGAMATSU T, YAIVIASAKI H: Generalsyntheses of 1-alkyltoxoflavin and 8-alkylfervenulin derivatives of biological significance by the regioselective alkylation of reumycin derivatives and the rates of transalkylation from 1-alkyltoxoflavins into nucleophiles. J. Chem. Soc. Perkin Trans. 1 (2001) :130–137.
   Google Scholar
• HONMA T, HAYASHI K, AOYAMA T et al.: Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J. Med. Chem. (2001) 44(26):4615–4627.
   PubMed Web of Science ®Google Scholar
• SKEHAN P, STORENG R, SCUDIERO D et al.: New colorimetric cytotoxicity assay for anticancer-drug screening. J. Nail. Cancer Inst. (1990) 82:1107–1112.
   PubMed Web of Science ®Google Scholar
• WANG S, MEADES C, WOOD G et al: 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem. (2004) 47(7):1662–1675.
   PubMed Web of Science ®Google Scholar
• WANG S, WOOD G, MEADES C et al: Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yppyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett. (2004) 14(16):4237–4240.
   PubMedGoogle Scholar
• BILODEAU MT, BALITZA AE, KOESTER TJ et al.: Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the herg ion channel. J. Med. Chem. (2004) 47(25):6363–6372.
   PubMed Web of Science ®Google Scholar
• METTEY Y, GOMPEL M, THOMAS V et al.: Aloisines, a new family of CDK/ GSK-3 inhibitors. SAP. study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. (2003) 46(2):222–236.
   Google Scholar
• GONZALEZ T, SEOANE M, CAAMANO P, VINUELA J, DOMINGUEZ F, ZALVIDE J et al.: Inhibition of CDK4 activity enhances translation of p27kipl in quiescent Rb-negative cells. J. Biol. Chem. (2003) 15(11):12689–12695.
   Google Scholar